Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267

验证使用荧光素酶标记的乳腺癌细胞系 MDA435LCC6 作为监测肿瘤进展和评估已上市抗癌药物多西他赛 (Dt) 单独使用或与 ILK 抑制剂 QLT0267 联合使用时的治疗活性的方法